Scientific and commercial innovation for pharma, biotech, academia and investors
John Martin is Professor of Cardiovascular Medicine at UCL. He is a scientist and clinician and founded the biotech company Ark Therapeutics, listed on the London Stock Exchange. He runs five Phase III trials of stem cells and heart disease. He has 20 patents granted…more ›
Dr. Wadsworth received his Ph.D. degree in virology from the University of Chicago in 1975 and carried out post-doctoral research in molecular biology at the University of California at San Franscisco from 1975 to 1978. He was a research scientist at the Worcester Foun…more ›
Degree in Biological Sciences, PhD in Molecular Medicine; currently senior researcher, Cell Biology and Neurosciences Department, Istituto Superiore di Sanità, Roma, Italy. Dr. Galli was active for more than 20 yrs as researcher in experimental oncology, cellular b…more ›
As the Chief Executive Officer of Genethon, Frédéric Revah has more than twenty years’ experience in the pharmaceutical and biotech industries as well as in academic research. Immediately prior to joining Genethon in January 2010, he had been Chief Executive O…more ›
Jane Farrar is a Professor and Lecturer in the Smurfit Institute of Genetics, School of Genetics and Microbiology, Trinity College Dublin and Co-Founder and Director of Genable Technologies Ltd, a company developing gene-based medicines for inherited ocular disorders. I…more ›
World Gene Therapy Congress Europe is a unique platform that links science, strategy and commercialisation with the latest solutions.
The 2012 World Gene Therapy Congress Europe is the senior director-level conference that tackles all the key scientific and technical issues facing the gene therapy industry and where decision-makers from the complete Gene Therapy value chain meet to learn and plan for the future.
It’s an exclusive gathering of the cutting edge companies and leading solution providers in the Gene Therapy industry.It is a place where innovation is showcased, solutions are found and learning is done.
Pharma, Biotech and Academia attend to learn about:
- Strategies for developing Gene Therapy markets
- Synergistic Gene Therapy advances with other biotechnologies
- Research, development and product approval
- Molecular biological advances for Gene Therapy
- Technologies and classification of successful Gene Therapy techniques
- Clinical applications and scale of Gene Therapy
- Regulatory and safety advances of Gene Therapy
- Licensing and collaborative Gene Therapy approaches
- Financing R&D and investor involvement
Who should attend:
- Pharmaceutical Companies
- Biotechnology Companies
- Gene Therapy Biotechnology Companies
- Government / Regulatory Bodies
- Academic/ Research Institutes
- NGOs / Public Health
- Contract Research Organisations
- Cell Line Suppliers / Platform Tech
- Equipment Manufacturers
- Medical Device / Technology Providers
- Venture Capital / Investors
- Consultants
- Law Firms
Who should sponsor:
- Pharma
- Biotechs
- Platform Technology
- CROs
- CMOs
- EQMs
- Automation companies
- Gene banks
- Law Firms
- Consultants
- Regional Development Agencies
- Distribution
